Market Newsdesk

Vertex Announces US FDA Approval for Expanded Use of CASGEVY^® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

– First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia –

– Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older –

– Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom –

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY^® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT.

“Just as we redefined what is possible in cystic fibrosis, our ambition is to transform the future for people living with sickle cell disease and transfusion-dependent beta thalassemia. The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “We’re deeply grateful to the patients, families and investigators who participated in the clinical trials that led to this historic approval, and we are ready to bring CASGEVY to children and their families across the U.S.”

“Today’s approval offers renewed hope for children living with sickle cell disease or transfusion‑dependent beta thalassemia,” said Haydar Frangoul, M.D., M.S., Medical Director of HCA Healthcare’s Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Children’s Hospital, investigator with Sarah Cannon Research Institute (SCRI) and Member of Vertex’s SCD Program Steering Committee. “Earlier access to the transformative potential of this therapy will allow clinicians and families to consider treatment before years of cumulative damage from these life-shortening diseases take hold.”

Vertex has established a network of independently operated, authorized treatment centers (ATCs) throughout the U.S. to offer CASGEVY to eligible patients through existing access and reimbursement pathways. Today, there are more than 75 activated ATCs in the U.S. The full list can be accessed at CASGEVY.com.

About Sickle Cell Disease (SCD)

Sickle cell disease (SCD) is a rare serious, inherited blood disease that is progressive and life‑shortening. The disease causes red blood cells to become rigid and misshapen, restricting blood flow and oxygen delivery to vital organs. Recurrent vaso‑occlusive crises (VOCs), unpredictable episodes of severe pain caused by blocked blood vessels, are a defining feature of SCD and frequently require hospitalization. Many patients experience these complications early in life, and over time, repeated VOCs and chronic anemia lead to progressive and irreversible organ damage, including damage to the brain, lungs, kidneys and heart. SCD places a substantial burden on patients and their families, who must manage frequent medical visits, hospitalizations, school and work disruptions, and the emotional toll of chronic pain and life‑threatening complications. Despite lifelong treatment, people with SCD and recurrent VOCs in the U.S. face shortened life expectancy, with a median age of death of approximately 45 years, report quality‑of‑life scores far below the general population and the estimated lifetime healthcare costs of managing the disease are $4–6 million.

About Transfusion‑Dependent Beta Thalassemia (TDT)

Transfusion‑dependent beta thalassemia (TDT) is a rare serious, inherited blood disease that is progressive and life‑shortening. The disease impairs the body’s ability to produce sufficient hemoglobin, limiting oxygen delivery to tissues and organs. People with TDT do not have enough functional hemoglobin in their red blood cells and require regular, lifelong blood transfusions, often beginning early in childhood, along with ongoing iron chelation therapy. While transfusions are necessary for survival, many of the long‑term complications of TDT are exacerbated by chronic transfusion therapy and iron overload and cumulative damage to the heart, liver and endocrine system, as well as bone abnormalities and delayed growth and puberty. TDT places a significant and ongoing burden on patients and their families, requiring frequent medical visits and complex lifelong treatment. Despite lifelong treatment, people with TDT in the U.S. face shortened life expectancy, with a median age of death of approximately 37 years, reduced quality of life and productivity, and the estimated lifetime healthcare costs of managing the disease are $5–5.7 million.

About CASGEVY^® (exagamglogene autotemcel)

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown in clinical trials to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT.

In the United States, CASGEVY was approved using the Commissioner’s National Priority Voucher. Vertex has also recently completed regulatory submissions in the Kingdom of Saudi Arabia and United Kingdom to expand the use of CASGEVY to children as young as five.

About the CLIMB Studies

The completed Phase 1/2/3 open-label studies, CLIMB-111 and CLIMB-121, were designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12-35 years with TDT or with SCD and recurrent VOCs. Patients were followed for approximately two years after CASGEVY infusion in these studies. CLIMB-141 and CLIMB-151 are ongoing Phase 3 open-label studies, designed to assess the safety and efficacy of a single dose of exagamglogene autotemcel in patients ages 2-11 years with TDT or with SCD and recurrent VOCs. Enrollment and dosing are complete for the 5–11-year-old cohort in both studies.

Each patient in these studies is asked to participate in the ongoing long-term, open-label study, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients with up to 15 years of follow up after CASGEVY infusion.

U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY

INDICATION

CASGEVY is indicated for the treatment of patients aged 2 years and older with:

• sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs)

• transfusion-dependent β-thalassemia (TDT)

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Neutrophil Engraftment Failure

There is potential risk of neutrophil engraftment failure after treatment with CASGEVY. In the clinical trials, all treated patients achieved neutrophil engraftment and no patients received rescue CD34⁺ cells.

Monitor absolute neutrophil counts (ANC) and manage infections according to standard guidelines and medical judgement. In the event of neutrophil engraftment failure, patients should be infused with rescue CD34⁺ cells.

Granulocyte colony-stimulating factor (G-CSF) is not recommended for 21 days after CASGEVY infusion.

Delayed Platelet Engraftment

Delayed platelet engraftment has been observed with CASGEVY treatment. There is an increased risk of bleeding until platelet engraftment is achieved.

Monitor patients for bleeding according to standard guidelines and medical judgement. Conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved. Perform blood cell count determination and other appropriate testing whenever clinical symptoms suggestive of bleeding arise.

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis can occur due to dimethyl sulfoxide (DMSO) or dextran 40 in the cryopreservation solution. Monitor patients for hypersensitivity reactions during and after infusion.

Off-Target Genome Editing Risk

The risk of unintended, off-target editing in an individual’s CD34⁺ cells cannot be ruled out due to genetic variants. The clinical significance of potential off-target editing is unknown.

ADVERSE REACTIONS

The most common Grade 3 or 4 non‑laboratory adverse reactions (occurring in ≥ 25%) were mucositis and febrile neutropenia in patients with SCD and patients with TDT, and decreased appetite in patients with SCD.

All (100%) of the patients with TDT and SCD experienced Grade 3 or 4 neutropenia and thrombocytopenia. Other common Grade 3 or 4 laboratory abnormalities (≥ 50%) include leukopenia, anemia, and lymphopenia.

DRUG INTERACTIONS

No formal drug interaction studies have been performed. CASGEVY is not expected to interact with the hepatic cytochrome P450 family of enzymes or drug transporters.

Use of Granulocyte-Colony Stimulating Factor (G-CSF): G-CSF must not be used for CD34⁺ HSC mobilization of patients with SCD.

Use of Hydroxyurea: Discontinue the use of hydroxyurea at least 8 weeks prior to start of each mobilization cycle and conditioning. There is no experience of the use of hydroxyurea after CASGEVY infusion.

Use of Crizanlizumab: Discontinue the use of crizanlizumab at least 8 weeks prior to start of mobilization and conditioning, as their interaction potential with mobilization and myeloablative conditioning agents is not known.

Use of Iron Chelators: Discontinue the use of iron chelators at least 7 days prior to initiation of myeloablative conditioning, due to potential interaction with the conditioning agent. Some iron chelators are myelosuppressive. If iron chelation is required, avoid the use of non-myelosuppressive iron chelators for at least 3 months and use of myelosuppressive iron chelators for at least 6 months after CASGEVY infusion. Phlebotomy can be used instead of iron chelation, when appropriate.

USE IN SPECIFIC POPULATIONS

Pregnancy/Lactation: CASGEVY must not be administered during pregnancy and breastfeeding should be discontinued during conditioning because of the risks associated with myeloablative conditioning. Pregnancy and breastfeeding after CASGEVY infusion should be discussed with the treating physician.

Females and Males of Reproductive Potential: A negative serum pregnancy test must be confirmed prior to the start of each mobilization cycle and reconfirmed prior to myeloablative conditioning.

Women of childbearing potential and men capable of fathering a child should use effective methods of contraception from start of mobilization through at least 6 months after administration of CASGEVY. Advise patients of the risks associated with conditioning agents.

Infertility has been observed with myeloablative conditioning, therefore, advise patients of fertility preservation options before treatment, if appropriate.

Please see full Prescribing Information for CASGEVY.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 16 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Reshma Kewalramani, M.D., and Haydar Frangoul, M.D., M.S., in this press release, statements regarding the expected clinical benefits of CASGEVY, expectations regarding the eligible patient population, and expectations for patient access to CASGEVY. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include the risks listed under the heading “Risk Factors” in Vertex’s annual report and in subsequent filings filed with the Securities and Exchange Commission at www.sec.gov and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701379449/en/

Vertex Pharmaceuticals Incorporated


Investors:

[email protected] or

+1 617-341-6108

Media:

[email protected] or

617-341-6992

KEYWORDS: United States United Kingdom North America Saudi Arabia Middle East Europe Massachusetts

INDUSTRY KEYWORDS: Children Biotechnology FDA Other Health Health Pharmaceutical Health Technology Medical Devices Genetics Consumer Clinical Trials

MEDIA:

Logo

Faraday Future Showcases its EAI Robotics Education Ecosystem at ISTE Live 2026 in Orlando, Drawing Strong Interest from Major North American Education Distributors and Procurement Leaders

• ISTE’s expanded collaboration with ASCD attracted top-level district leaders and procurement decision-makers; established ed-tech distributors expressed strong interest in FF’s EAI robotics ecosystem, underscoring that Physical AI combined with education represents an irreversible trend in school district procurement and family education.

• FF’s ISTE presence follows the Company’s comprehensive June product launches. FF showcased the complete lineup for the Six-series Full-form FF EAI Robot World, launched its new mobile manipulators, completed the launch of the All-New Futurist, FX Navi, and gave a preview of FF’s EAI Robotics Industrial Ecosystem.

• FF launched the world’s first Three-in-One EAI robotics education ecosystem, designed for both B2C family education and B2B educational institutions.

ORLANDO, Fla.–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today recapped FF’s involvement in ISTE Live 2026 in Orlando, the largest education technology conference in North America. FF used this opportunity to showcase its newest robotics and advance collaboration with K–12 schools, educational institutions, FF Par partners, developers, and ecosystem partners. The Company continues to further showcase FF’s latest progress across multi-form robotics, device capabilities, real-world applications, and ecosystem development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701965638/en/

ISTE’s mission is to empower educators to reimagine and redesign learning through impactful pedagogy and meaningful technology use. They achieve this by offering transformative professional learning, fostering vibrant communities, and ensuring that digital tools and experiences are accessible and effective. This year’s event also represented a significant milestone, as ISTE deepened its collaboration with ASCD (Association for Supervision and Curriculum Development), drawing an expanded audience of school district superintendents, chief information officers (CIOs), and large-scale procurement decision-makers from across the United States — further elevating the conference’s profile as a premier B2B education technology channel.

The ISTE event allowed FF to showcase its newest robotics including All-New Futurist and Navi and follows the Company’s recent multi-faceted product and innovation launches in June where FF showcased the complete lineup for the Six-series Full-form FF EAI Robot World, launched its new mobile manipulator, completed the second-half launch of the All-New Futurist, and gave a preview of FF’s EAI Robotics Industrial Ecosystem.

FF also recently launched its FF EAI Education Ecosystem strategy, the world’s first Three-in-One EAI robotics education ecosystem, designed for both B2C family education and B2B educational institutions under the theme “Grow with EAI” — growing alongside Physical AI. Built on FF’s global EAI industry bridge strategy and powered by its Three-in-One ecosystem strategy, the FF EAI Robotics Education ecosystem is a complete solution and education system.

At the conference, FF engaged in extensive discussions with well-established education technology distributors and content providers. These experienced industry players expressed strong interest in FF’s Embodied AI products and comprehensive Three-in-One ecosystem approach. While traditional programmable robots remain prevalent across the exhibition floor, very few exhibitors are offering solutions centered on Physical AI and open large-model robotics platforms such as FF’s open EAI Brain. The positive reception from these leading channel partners signals that FF, as a new entrant in the Embodied AI education track, has quickly captured the attention of mainstream North American distribution channels.

For B2C users, the ecosystem is designed to enable the first wave of families to bring robots into the home, helping children enter the world of Physical AI earlier and shape an AI-native generation.

For B2B users, FF’s EAI education ecosystem is designed to empower research and education across the full value chain. Scaled device deployment, an open-source and open EAI Brain, and the Data Factory together create unique value for the research and education sector. FF’s integrated ecosystem of devices, data, and open EAI Brain directly addresses the growing demand among school districts for seamless hardware-software integration and technology-enhanced instruction, demonstrating that FF’s product and ecosystem layout is well-aligned with the procurement priorities of mainstream North American education channels. Conversations with experienced vendors at the conference reinforced a shared conviction that Physical AI combined with education represents an irreversible trend in next-generation school district procurement and family education, further validating FF’s “Grow with EAI” strategy.

By making family education the first B2C entry point for EAI robots, FF aims to unlock the home market and create more consumer use cases for EAI robots.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a Three-in-One ecosystem of “Device, Data, EAI Brain & Open-Source and Open Platform,” FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding potential future legal actions against alleged illegal market manipulation or similar improper activities, and FF’s entry into the embodied AI robotics market and robotics deliveries and development, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to timely regain compliance with Nasdaq’s minimum bid requirement; the Company’s common stock will be suspended from trading on Nasdaq if it’s closing price is $0.10 or less for 10 consecutive trading days; the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; the willingness of convertible debt investors to fund the Company while it lacks sufficient share capital for conversions; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the Company’s reliance on a single OEM for most of its robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701965638/en/

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Other Education Artificial Intelligence Robotics Family Technology Primary/Secondary Consumer Education

MEDIA:

Photo

Faraday Future Showcases its EAI Robotics Education Ecosystem at ISTE Live 2026 in Orlando, Drawing Strong Interest from Major North American Education Distributors and Procurement Leaders

Photo

Faraday Future Showcases its EAI Robotics Education Ecosystem at ISTE Live 2026 in Orlando, Drawing Strong Interest from Major North American Education Distributors and Procurement Leaders

Logo

Solid Power Appoints Uwe Breitweg to Board of Directors, Adding Deep Automotive and Battery Strategy Expertise

• Mr. Breitweg brings more than two decades of automotive leadership, with deep expertise in battery strategy, powertrain development, and vehicle engineering
• Appointment made pursuant to BMW Holding B.V.’s director nomination rights

 

LOUISVILLE, Colo.–(BUSINESS WIRE)–Solid Power, Inc. (Nasdaq: SLDP), a leading U.S.-based developer of solid-state battery technology, today announced the appointment of Uwe Breitweg, Vice President Powertrain, Emission and Battery Strategy of the BMW Group, to its board of directors, effective July 1, 2026. His appointment underscores BMW continuing to work very closely together with Solid Power as a strategic development partner in this future key technology.

“Mr. Breitweg brings to Solid Power an exceptional combination of technical depth and strategic leadership across battery and vehicle engineering at one of the world’s premier automotive companies,” said John Van Scoter, President and CEO of Solid Power. “His perspective will be invaluable as we continue to advance our solid-state technology and execute our strategy with automotive and cell manufacturing partners around the world. On behalf of the entire board, I welcome him to the team. I would also like to thank Dr. Feurer for his dedicated service and many contributions to Solid Power during his tenure on the board.”

Mr. Breitweg has more than two decades of leadership experience in the global automotive industry, with deep expertise in battery strategy, powertrain development, and vehicle engineering. He currently serves as Vice President Powertrain, Emission and Battery Strategy for the BMW Group, a role he has held since 2021. Previously, he served as Vice President Powertrain Systems Industrial Customers from 2016 to 2021 at the BMW Group.

About Solid Power, Inc.

Solid Power is developing solid-state battery technology to enable the next generation of batteries for the fast-growing EV and other markets. Solid Power’s core technology is its electrolyte material, which Solid Power believes can enable extended driving range, longer battery life, improved safety, and lower cost compared to traditional lithium-ion. Solid Power’s business model – selling its electrolyte to cell manufacturers and licensing its cell designs and manufacturing processes – distinguishes the company from many of its competitors who plan to be commercial battery manufacturers. Ultimately, Solid Power endeavors to be a leading producer and distributor of sulfide-based solid electrolyte material for powering both EVs and other applications. For more information, visit http://www.solidpowerbattery.com/.

Forward-Looking Statements

All statements other than statements of present or historical fact contained herein are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including Solid Power’s or its management team’s expectations, objectives, beliefs, intentions or strategies regarding the future. When used herein, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan,” “outlook,” “seek,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements may include, but are not limited to, statements regarding Solid Power’s technology, strategy, business model, market opportunity, operations, future prospects, and plans and objectives of management. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Solid Power disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. Readers are cautioned not to put undue reliance on forward-looking statements and Solid Power cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Solid Power, including the following factors: (i) risks relating to the uncertainty of the success of our research and development efforts, including our ability to achieve the technological objectives or results that our partners require and our ability to commercialize our technology in advance of competing technologies and our competitors; (ii) risks relating to our status as a research and development stage company with a history of financial losses with an expectation of incurring significant expenses and continuing losses for the foreseeable future, including execution of our business plan and the timing of expected business milestones; (iii) risks relating to the non-exclusive nature of our partnerships, our ability to secure new business relationships, and our ability to manage these relationships; (iv) our ability to negotiate and execute commercial agreements with our partners and customers on commercially reasonable terms; (v) broad market adoption of EVs and other technologies where we are able to deploy our technology, if developed successfully; (vi) our success attracting and retaining our executive officers, key employees, and other qualified personnel; (vii) our ability to protect and maintain our owned and exclusively-licensed intellectual property, including in jurisdictions outside of the United States; (viii) our ability to secure government contracts and grants, changes in government priorities with respect to our government contracts and grants or government funding reductions or delays, and the availability of government subsidies and economic incentives; (ix) delays in the construction and operation of facilities that meet our short-term research and development and long-term electrolyte production requirements; (x) changes in applicable laws or regulations, including tariffs; (xi) risks relating to, and potential liabilities resulting from, our information technology infrastructure and data security incidents, threats, breaches, or attacks; and (xii) risks relating to other economic, business, or competitive factors in the United States and other jurisdictions, including supply chain interruptions and changes in market conditions, and our ability to manage these risks and uncertainties. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the “Risk Factors” sections of Solid Power’s Annual Report on Form 10-K for the year ended December 31, 2025, Solid Power’s Quarterly Report on Form 10-Q for the quarter ended March 31 2026, and other documents filed by Solid Power from time to time with the Securities and Exchange Commission (the “SEC”), all of which are available on the SEC’s website at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Solid Power gives no assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701258298/en/

[email protected]

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Mobile/Wireless EV/Electric Vehicles Other Energy Alternative Energy Batteries Energy Technology Automotive Other Manufacturing Environment Green Technology Automotive Manufacturing Manufacturing

MEDIA:

Logo

UFC Delivers Knockout Results for Sydney

UFC 325 Generated AUD $65.7M in Economic Impact for Sydney Metro Area

SYDNEY–(BUSINESS WIRE)–UFC^®, the world’s premier mixed martial arts organization, today announced that UFC 325: VOLKANOVSKI vs. LOPES 2, which took place earlier this year at Sydney’s Qudos Bank Arena, sparked significant economic impact, generating AUD $65.7M^* throughout the Sydney metro area.

In the main event, Australia’s own Alex Volkanovski defeated Diego Lopes to retain the undisputed UFC Featherweight Championship. UFC 325 drew a sold-out crowd of 18,102 and set the Qudos Bank Arena gate revenue record with AUD $14.4M, making it the highest-grossing event at any indoor arena in Australian history and eclipsing the record established by UFC 312: DU PLESSIS vs. STRICKLAND 2 in February 2025. In line with UFC’s previous events and high visitation trends, over 69% of attendees, or approximately 12,550 fans, travelled to Sydney for UFC 325.

“UFC events are unlike anything else – it’s the best show in sports,” said Peter Kloczko, Senior Vice President of UFC Australia and New Zealand. “We are thrilled to continue producing world-class events that create amazing fan experiences while delivering industry-leading outcomes for our event partners and the tourism economy.”

UFC 325 supported over 340 local jobs while contributing AUD $16.5M in salaries and wages. In addition, Goods and Services Tax (GST) paid by UFC on ticket sales generated approximately AUD $1.3M, which is distributed among Australian states to fund healthcare, education, justice, welfare, public housing and other essential services.

UFC has delivered three sold-out UFC Numbered Events at Qudos Bank Arena since 2023: UFC 293: ADESANYA vs. STRICKLAND in September 2023, UFC 312: DU PLESSIS vs. STRICKLAND 2 in February 2025, and UFC 325: VOLKANOVSKI vs. LOPES 2 in February this year.

Combined, these events have seen a total economic impact of AUD $189.6M, a direct impact of AUD $70M, and a total of 35,734 out-of-town visitors to Sydney, with out-of-town visitors accounting for an average of 65% of attendees per UFC event.

Australia has consistently demonstrated that it is one of the strongest pound-for-pound UFC markets in the world. In turn, UFC events have continued to deliver outstanding results for the host cities across Australia and produce thrilling, unforgettable moments for Australia’s loyal UFC fans.

^*Source: The figures were determined through a study conducted by research firm Applied Analysis and commissioned by UFC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701009981/en/

Press Contact:

UFC

Arabella Crouch

[email protected]

KEYWORDS: Australia/Oceania Australia

INDUSTRY KEYWORDS: Entertainment Martial Arts Sports Events/Concerts

MEDIA:

Logo